Home
NewsNewsINVO Fertility partners with Heidi Health to integrate an AI-powered scribe at Wisconsin Fertility Institute, streamlining documentation so clinicians focus on care.
INVO Fertility, a healthcare fertility company committed to expanding access to advanced treatment through clinic operations and technological innovation, has announced a strategic alliance with Heidi Health to deploy its AI-powered scribe platform at the Wisconsin Fertility Institute (WFI).
The collaboration marks a key step in INVO Fertility’s efforts to enhance clinical efficiency and patient care through digital transformation. Heidi Health’s AI-driven platform is built by doctors and integrates seamlessly with existing EHR systems, allowing providers to automate documentation without overhauling their digital infrastructure. By adapting to each physician’s preferred note-taking style, the system generates precise and personalized clinical documentation, cutting down administrative time and cognitive strain for medical teams.
The system currently supports nearly 2 million patient interactions each week and is used in more than 50 countries, in over 200 specialties, and across more than 110 languages. “We’re thrilled to collaborate with INVO Fertility and WFI to bring our AI-driven tools to Wisconsin patients,” said Dr. Thomas Kelly, CEO and co-founder of Heidi Health. “Heidi’s AI scribe automates an average of over two hours of daily administrative work, transcribing and processing clinician-patient conversations, producing clinical notes and follow-up materials so clinicians can focus on delivering quality care to their patients.”
For fertility specialists at INVO’s Wisconsin Fertility Institute, the integration of Heidi AI Scribe will mean the automation of patient consultation transcription, creating accurate records, case histories, and administrative files in real time. This efficiency is particularly crucial in reproductive medicine, where providers manage both the emotional and medical complexity of infertility care. The technology is expected to reduce manual note-taking by as much as 80%, enabling doctors to engage more meaningfully with patients, strengthen trust, and refine individualized treatment plans.
Dr. Gretchen Collins, medical director and Reproductive Endocrinologist and Infertility specialist at the Wisconsin Fertility Institute, shared her enthusiasm for the initiative. “We are excited to be partnering with Heidi Health to find ways to continually elevate the patient experience at our Wisconsin clinic, ensuring every individual feels supported each step of the way. This technology empowers our team to focus on what matters most – building families.”
According to Steve Shum, CEO of INVO Fertility, the move continues the company’s trajectory toward innovation and patient-first care. “This partnership builds on INVO Fertility’s series of recent advancements to bring cutting-edge technology and advanced treatment options to our Wisconsin-based facility,” he stated. “Moving forward, we will continually look at new ways to ensure we achieve our mission to empower families with the tools and expertise they need to achieve their dreams of parenthood.”
By leveraging Heidi Health’s AI-powered scribe technology, INVO Fertility aims to streamline documentation while preserving the empathy and attention that define fertility care. The partnership underscores a shared vision of using intelligent automation to enhance clinical efficiency and deepen patient engagement a milestone in INVO Fertility’s mission to redefine accessibility and experience in reproductive healthcare.
A groundbreaking Nature Medicine study compares AI deep learning against expert embryologists in selecting embryos. While pregnancy rates remain comparable, the study uncovers a massive advantage in efficiency that could revolutionize IVF labs worldwide. Discover how AI-driven embryo selection accuracy is reshaping the future of fertility treatment.
FertilAI has received EU MDR clearance for tools advancing Predictive AI in Fertility through its Fertilane platform. StimAI and OvuPredict help clinicians optimise IVF timing, predict ovulation and improve scheduling efficiency. The technology supports scalable fertility care, reduced monitoring needs and better patient treatment experiences globally.
The Ferring Global Fertility Monitor has been launched by Ferring Pharmaceuticals and Gallup to examine fertility trends in 70 countries. Through large-scale surveys, the project will explore economic, social, and cultural influences on parenthood decisions. Insights are expected to guide policy, healthcare planning, and future demographic strategies.
Maven Clinic has expanded its Fertility and Family Building program with earlier diagnostics, wearable integration, and AI-powered personalised care. The enhanced platform supports faster diagnosis, improved treatment decisions, and condition-specific pathways for PCOS, endometriosis, and oncofertility. The rollout continues through 2026 with added innovations and partnerships.
Germany is debating the legalization of egg donation in Germany, challenging decades-old restrictions under the Embryo Protection Act. Experts argue reform is overdue to align with modern reproductive science, reduce fertility tourism, and improve patient care, while policymakers work to balance ethical concerns with growing demand for advanced fertility treatments.
A new review highlights the link from Forever Chemicals to reduced ART outcomes, showing how PFAS exposure impacts fertility, pregnancy, and reproductive health. The findings raise urgent concerns for IVF patients and call for stronger regulation, deeper research, and systemic action to address environmental risks in reproductive medicine.
The 2027 Title X NOFO introduces a major policy shift toward addressing infertility crisis in the U.S. It mandates basic infertility services, expands male reproductive health focus, and promotes education on body literacy and lifestyle factors, aiming to support family formation alongside traditional contraceptive services.
